Metabolomics Screening for ALK and ROS-1 Kinase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating drug efficacy in non-small cell lung cancer, particularly for ALK and ROS-1 kinase inhibitors, are limited by the lack of efficient biomarkers and high-throughput screening techniques, making it difficult to identify effective candidates early in drug development.
Innovation Solution
A method involving the measurement and comparison of adenosine, AMP, and cAMP metabolite levels in cell lines treated with candidate substances to screen for ALK or ROS-1 kinase inhibitors, utilizing metabolomics techniques for comprehensive analysis and biomarker identification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional molecular biological experimental methods are used for drug screening, then the evaluation process is simple and straightforward, but the throughput is low and simultaneous quantitative and qualitative analysis in large quantities is not possible
Solution Approach 1:
The patent replaces conventional molecular biological experimental methods with metabolomics technology, specifically using mass spectrometry-based metabolic profiling to screen ALK/ROS-1 kinase inhibitors. This substitution enables high-throughput simultaneous quantitative and qualitative analysis of metabolites, dramatically increasing screening throughput while maintaining analytical capability through advanced mass spectrometry systems
Solution Approach 2:
The patent introduces metabolomics parameters (metabolite levels, metabolic pathway activity) as new evaluation dimensions for drug screening. By measuring changes in metabolic parameters such as amino acid metabolism, energy metabolism, and nucleotide metabolism, the system achieves comprehensive high-throughput evaluation of candidate compounds' effects on cancer cell metabolism
2Measurement precision
If metabolomics technique is introduced for high-throughput screening, then simultaneous quantitative and qualitative analysis in large quantities becomes possible, but the complexity of the screening system increases
Solution Approach 1:
The patent uses metabolites as intermediary markers to reflect the biological effects of ALK/ROS-1 kinase inhibitors. By measuring metabolite levels (such as ATP, amino acids, nucleotides) that mediate between drug treatment and cellular response, the system achieves precise evaluation of drug efficacy through metabolic changes without directly measuring complex molecular biological parameters
Solution Approach 2:
The metabolomics platform serves multiple functions simultaneously: it performs qualitative identification of metabolites, quantitative measurement of metabolite concentrations, and pathway-level analysis of metabolic changes. This multi-functionality allows a single system to provide comprehensive evaluation data for drug screening, reducing the need for multiple separate analytical systems
3Reliability
If current biomarker-based screening methods are used, then the screening process is straightforward, but efficient biomarkers for ALK and ROS-1 kinase inhibitors are lacking, making it difficult to identify effective candidates early
Solution Approach 1:
The patent performs preliminary identification of metabolic biomarkers specific to ALK/ROS-1 kinase inhibitor activity before full-scale drug screening. By establishing baseline metabolic profiles and identifying key metabolite changes associated with known inhibitors, the system creates a reference framework that enables rapid and reliable identification of effective candidates in subsequent screening, reducing time for later validation phases
Solution Approach 2:
The patent implements feedback mechanisms where metabolite measurement results are continuously used to refine and optimize the screening process. By monitoring metabolic changes in real-time and comparing against established biomarker profiles, the system provides feedback on candidate compound efficacy, enabling rapid iteration and identification of effective inhibitors while reducing overall development time
Data Source
AI summary
A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.